Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Personlig tilpasset genomikk for screening av prenatale abnormiteter ved bruk av mors blod (PEGASUS-2)

12. november 2026 oppdatert av: François Rousseau, CHU de Quebec-Universite Laval

Personlig tilpasset genomikk for screening av prenatale abnormiteter ved bruk av mors blod: Mot første nivå screening og utover

This project aims to provide high- quality evidence to inform decisions by health care organisations about using first-tier non-invasive prenatal screening (NIPS) to replace traditional screening tests for trisomy 21, and potentially to screen for other fetal chromosome anomalies. We will compare the current screening approach of second-tier NIPS with the use of first-tier NIPS in a large cohort of pregnant women.

Studieoversikt

Detaljert beskrivelse

There is some data on the performance of NIPS as a first tier screening test but our systematic review has shown that no trial comparing the effectiveness (utility) of 2nd-tier NIPS with that of first-tier NIPS has been published . Further it is important for health care decision makers to have evidence produced in Canada since the geographical context of healthcare can affect uptake as well as patient decision and thus their healthcare trajectories. There is a need for a trial that is between an explanatory trial and a pragmatic trial to provide the types of answer that we aim to document in the present state of knowledge on NIPS-based screening strategies in Canada. Our Objective is to perform a pan-Canadian large-scale comparative utility (clinical outcomes) study of first-tier NIPS (expanded or not) as compared to the new standard of care (NIPS as a 2nd tier test performed much later during pregnancy and only in high risk pregnancies).

Studietype

Intervensjonell

Registrering (Faktiske)

7849

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 1P2
        • Kelowna Regional Fertility Center
      • Prince Rupert, British Columbia, Canada, V8J 2A6
        • Prince Rupert Regional Hospital
      • Vancouver, British Columbia, Canada, V6H 3N1
        • Children's & Women's Health Centre
    • Quebec
      • Montreal, Quebec, Canada, H3T 1C5
        • CHU Ste-Justine
      • Québec, Quebec, Canada, G1L3L5
        • CHU de Québec - Université Laval
      • Sept-Îles, Quebec, Canada, G4R 0N9
        • CIUSSS Côte-Nord

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

19 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Pregnant women 19 years or older wanting prenatal screening
  • 10-13+6 wks determined by dating ultrasound or last menstrual period.
  • Not intending to pursue self pay NIPT

Exclusion Criteria:

  • Known fetal anomaly at the time of recruitment
  • Multiple gestation
  • Known twin demise
  • Planned CVS or amnio for known genetic condition.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Screening
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Standard of care (2nd tier NIPS)

For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).

biochemical prenatal screening with or without nuchal translucency by US

Andre navn:
  • IPS

genomics based NIPS after a positive traditional prenatal screen

Andre navn:
  • andre lag ikke-invasiv prenatal testing (NIPT)

amniocentesis or chorionic villi sampling (CVS)

Eksperimentell: First-tier NIPS

For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).

amniocentesis or chorionic villi sampling (CVS)

genomics based NIPS at first trimester

Andre navn:
  • første lag NIPT, Universal NIPS, Universal NIPT

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Gestational age at diagnosis
Tidsramme: Up to 24 weeks of gestational age

gestational age at final result in the sub-set of participants that have received a positive NIPS result and that have been offered diagnostic testing

Up to 24 weeks of gestational age

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Gestational age at negative screening result
Tidsramme: Up to 24 weeks of gestational age

gestational age at final result in the sub-set of participants that have received a negative screening result

Up to 24 weeks of gestational age
Gestational age at positive screening result
Tidsramme: Up to 24 weeks of gestational age

gestational age at final result in the sub-set of participants that have received a positive screening result

Up to 24 weeks of gestational age
proportion of women with no results
Tidsramme: Up to 24 weeks of gestational age

proportion of women with no NIPS result at first and second attempt

Up to 24 weeks of gestational age
numbers of days for women with false positive result of screen to wait for result of definite test
Tidsramme: Up to 24 weeks of gestational age

Difference between gestational age (in days) at first positive prenatal screening result and final negative screening result

Up to 24 weeks of gestational age
Change in PROMIS-29 Score
Tidsramme: At weeks of gestation 10-13, week 16 and week 22

The PROMIS-29 assesses seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and ability to participate in social roles and activities. Each of the seven domains has four questions which are scored on a five-point Likert scale. The PROMIS-29 scales will be scored using a T-score metric method available at the Assessment Center website (http://assessmentcenter.net). A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores mean more of the specific scale's construct, which may indicate a desirable or an undesirable outcome. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation.

At weeks of gestation 10-13, week 16 and week 22
Change in PROMIS Emotional Distress - Anxiety - Short Form 8a Score
Tidsramme: At weeks of gestation 10-13, 16 and 22

The PROMIS-Anxiety short form assesses anxiety with 8 questions. The form includes 8 items and uses a scale of 1-5 (1=Never, 2=Almost never, 3= Sometimes, 4=Often, 5=Almost always). The raw score is the sum of the points for each response. A higher than average raw score indicates higher than average anxiety. A higher score represents higher levels of anxiety. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation.

At weeks of gestation 10-13, 16 and 22
Patient-Reported Experience Measure (PREM) - Score
Tidsramme: At 22 weeks of gestation

A 17-questions validated PREM questionnaire on pregnancy experience that measures three dimensions - type of prenatal care received and test results (seven questions), pregnancy visits (four questions (scales 1-5) and prenatal screening experience (six questions).

A profile score by looking at frequencies of responses for each item will be used.

At 22 weeks of gestation
gestational age at termination of pregnancy
Tidsramme: Up to 24 weeks of gestational age

Gestational age at termination of pregnancy for participants having volountary termination

Up to 24 weeks of gestational age
percentage of women undergoing invasive diagnostic testing
Tidsramme: Up to 24 weeks of gestational age

see outcome title

Up to 24 weeks of gestational age

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Sylvie Langlois, MD FRCPC, University of British Columbia
  • Hovedetterforsker: Francois Rousseau, MD MSc FRCPC, CHU de Québec - Université Laval

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. januar 2020

Primær fullføring (Faktiske)

30. september 2024

Studiet fullført (Faktiske)

30. juni 2026

Datoer for studieregistrering

Først innsendt

21. januar 2019

Først innsendt som oppfylte QC-kriteriene

4. februar 2019

Først lagt ut (Faktiske)

5. februar 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere